Birgitta Versluijs

150 Supplemental data TABLE S2. Univariate predictor analyses for Allo-LS free survival, BOS (N=23) Variable HR (95% CI), P value Age at Allo-LS 1.01 (0.91-1.12), p=0.92 Female 5.65 (1.22-26.1), p=0.03 Primary disease  Malignant  Bone marrow failure syndrome  Inborn error of metabolism  Primary Immune deficiency 1 1.17 (0.24-5.65), p=0.85 NA 2.76 (0.46-16.62), p=0.27 Stem cell source  Bone marrow  Cord blood  Peripheral blood stem cells 1 NA NA Unrelated donor 1.04 (0.31-3.45), p=0.95 Conditioning regimen  Myeloablative Busulfan based  Myeloablative total body irridiation (TBI) based  Non-myeloablative/reduced intensity conditioning (RIC)  1 1.0(0.04-228), p=1.0 1.0 (0.0-555), p=1.0 Human Leukocyte Antigen (HLA) mismatched* 1.94 (0.61-6.15), p=0.26 Hematopoietic cell transplantation (HCT) before 2008 0.9 (0.28-2.84) p=0.85 Respiratory viruses from broncho-alveolar lavage pre-HCT (n=16) 1.01 (0.25-4.10) p=0.99 Respiratory viruses from nasopharyngeal aspirate pre-HCT (n=19) 0.87 (0.23-3.29) p=0.84 Viral reactivation prior to Allo-LS 0.59 (0.17-1.96) p=0.39 Time from HCT to Allo-LS 0.99 (0.99-1.01) p=0.38 Time from symptoms to treatment Allo-LS 1.00 (0.98-1.02) p= 0.93 Graft versus Host Disease prior to Allo-LS 5.01 (1.00-25.10) p=0.05 Oxygen therapy 2.44 (0.65-9.11) p=0.18 Intensive care for mechanical ventilation 0.65 (0.14-2.99) p=0.58 High resolution CT composite score (n=22) 1.01 (0.95-1.06) p=0.86 High resolution CT allo score (n=22) 1.07 (0.93-1.25) p=0.35 Respiratory viruses from NPA or BAL at diagnosis Allo-LS (n=15) 0.94 (0.23-3.81) p=0.94 * All 10/10 bone marrow/peripheral blood stem cell products and 6/6 cord blood units were considered matched. Allo-LS, Alloimmune mediated lung syndrome. 8